Navigation Links
Rheumatoid Arthritis Patient Share of Actemra Projected to Exceed Patient Share of Cimzia and Simponi Among the Medicare Population
Date:11/3/2010

EXTON, Pa., Nov. 3, 2010 /PRNewswire/ -- Bio-Trends is pleased to announce the publication of a new syndicated report, TreatmentTrends®: Rheumatoid Arthritis Q3 2010.  This report covers the use of biologics for the treatment of rheumatoid arthritis (RA). The report, part of a quarterly series, focuses on current and future use of biologic agents, patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers' patient assistance programs.

Despite the availability of newer TNF-alpha inhibitors, the TNF refractory market still remains relatively large. As many as one-fourth of first-time biologic users ultimately require a switch to another biologic agent due to poor response or waning efficacy of TNF-alpha inhibitors. However, the newer TNF-alpha inhibitors and biologic agents with alternative mechanisms of action are still perceived as less efficacious and less safe compared to the established TNF-alpha inhibitors.

The patient market share for the newest biologic agent, Genentech-Roche's Actemra (launched in January 2010), is currently estimated to be less than 5 percent among biologic-treated, rheumatoid arthritis (RA) patients.  However, according to surveyed rheumatologists' projections, the patient share of Actemra among the Medicare RA population is projected to exceed the patient share estimates of UCB's Cimzia and Centocor Ortho Biotech's Simponi in the next six months.  Furthermore, the patient share of Actemra among rheumatologists with in-office-infusion capability is projected to increase by more than 50 percent in the next six months.  

Amgen/Pfizer's Enbrel and Abbott Labs' Humira are currently the preferred first- and second-line biologic agents, respectively, among surveyed rheumatologists for the treatment of RA. However, almost one-fifth of rheumatologists cited decreased usage of both Enbrel and Humira in the past six months and, overall, rheumatologists project significantly lower RA patient share for both agents in the next six months. Among rheumatologists who use Cimzia and Simponi, as many as one-third of their RA patients who are initiated on these newer TNF-alpha inhibitors are biologic-naive.  

About BioTrends Research Group, Inc.BioTrends Research Group, Inc. (www.bio-trends.com) provides syndicated market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets.   For information on BioTrends' publications and research capabilities, please contact us at (610) 363-3872 or www.bio-trends.com. BioTrends Research Group, Inc. is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:BioTrends Research Group, Inc.Decision Resources, Inc.Sharon Funk

Christopher Comfort404-223-2963

781-993-2597 sfunk@bio-trends.com   ccomfort@dresources.com
'/>"/>

SOURCE BioTrends Research Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. For the Treatment of Rheumatoid Arthritis, Surveyed European Rheumatologists Expect Well-Established TNF-Alpha Inhibitors to Lose Considerable Patient Share to Newer Agents in This Drug Class
2. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
3. Deadline Approaching for UCB Rheumatoid Arthritis Family Scholarship
4. CEL-SCI Study Shows CEL-2000 Vaccine Blocks Progression of Rheumatoid Arthritis
5. Enbrel Will Remain Decision Resources Clinical Gold Standard Through 2018 for the Treatment of Rheumatoid Arthritis
6. ChemoCentryx Initiates Phase 2 Clinical Trial of CCX354 for the Treatment of Rheumatoid Arthritis
7. New Market Research Report from BioTrends Provides Insight on How Rheumatologists are Utilizing Biologic Agents in the Treatment of Rheumatoid Arthritis
8. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
9. SIMPONI(TM) (golimumab) Receives European Approval as Once-Monthly Subcutaneous Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis with Novel SmartJect(TM) Autoinjector
10. Phytomedics Inc. Announces Publication of the Phase 2b Clinical Trial Results of an Extract of the Chinese Herbal Remedy Tripterygium wilfordii Hook F in Rheumatoid Arthritis
11. Rigels R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... , Dec. 6, 2016 Eurofins ... accreditation from the College of American Pathologists (CAP) ... (CLIA) for its new laboratory in ... moved its North American headquarters. "Our ... sequencing -- which is still considered the ,Gold ...
(Date:12/6/2016)... , Dec. 6, 2016 Two new disaster ... in a simulated mass casualty event Tuesday at John ... The technology debuted before an audience including ... representatives from Homeland Security, Federal Law Enforcement Agencies, and ... known as HiRO (Health Integrated Rescue Operations), was developed ...
(Date:12/6/2016)... , Dec. 6, 2016  Arcturus Therapeutics, Inc. ... company, announced today that it entered into collaboration ... therapeutics for the treatment of NASH and other ... delivery platform LUNAR™ and UNA Oligomer chemistry. The ... Takeda,s long-standing commitment to and expertise in GI ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a worldwide ... US market its advanced highly customizable contact technology solutions. , ODU Single Contact ... technologies are ideal for a wide range of applications that require customization from ...
(Date:12/7/2016)... ... December 07, 2016 , ... Baciocco Brothers Insurance Agency, ... in the Sacramento/Folsom region, is initiating a charity event to raise support and ... Another Chance treatment center in Sacramento works to provide area teens and families ...
(Date:12/7/2016)... ... December 07, 2016 , ... One of two inventors from ... securement tape is painful for her. "This is why the co-inventor and I have ... said. , They then created a prototype of the patent-pending AV-AIR, a device that ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... A. Kevin ... owners and families throughout the Five Boroughs, is launching a charity drive to raise ... to continue the traditions and spirit of marines and Navy FMF Corpsmen. Working closely ...
(Date:12/7/2016)... ... 2016 , ... Sharon Kleyne, host of the nationally syndicated radio program, The ... of America, declared on her radio program in November 2016 the need to educate ... bullies attack leaders in corporate America, they are trying to take advantage of successful ...
Breaking Medicine News(10 mins):